Pharmaron Sets 20 August 2026 Board Meeting to Approve 1H 2026 Interim Results

Bulletin Express

08/06

Pharmaron Beijing Co., Ltd. (Pharmaron) has issued a notice confirming that its board of directors will convene on 20 August 2026 to consider and approve the consolidated interim results for the six months ended 30 June 2026 and to authorize their publication.

The announcement, dated 6 August 2026 and signed by Chairman Dr. Lou Boliang, specifies that the session will take place in Beijing, the People’s Republic of China.

Pharmaron’s current board composition comprises: • Executive Directors: Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei • Employee Representative Director: Mr. Li Shing Chung Gilbert • Non-executive Director: Ms. Wan Xuan • Independent Non-executive Directors: Ms. Li Lihua, Prof. Tsang King Fung, Ms. Shen Rong

No additional financial details were disclosed in the notice. The forthcoming meeting will determine the release timetable and content of Pharmaron’s half-year financial statements for 2026.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1182061725"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182061725\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182061725?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 16:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182061725","market":"us","top_or_hot":-1,"title":"Pharmaron Sets 20 August 2026 Board Meeting to Approve 1H 2026 Interim Results","media":"Bulletin Express","content":"<p>Pharmaron Beijing Co., Ltd. (Pharmaron) has issued a notice confirming that its board of directors will convene on 20 August 2026 to consider and approve the consolidated interim results for the six months ended 30 June 2026 and to authorize their publication.</p>\n<p>The announcement, dated 6 August 2026 and signed by Chairman Dr. Lou Boliang, specifies that the session will take place in Beijing, the People’s Republic of China.</p>\n<p>Pharmaron’s current board composition comprises:\n• Executive Directors: Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei  \n• Employee Representative Director: Mr. Li Shing Chung Gilbert  \n• Non-executive Director: Ms. Wan Xuan  \n• Independent Non-executive Directors: Ms. Li Lihua, Prof. Tsang King Fung, Ms. Shen Rong</p>\n<p>No additional financial details were disclosed in the notice. The forthcoming meeting will determine the release timetable and content of Pharmaron’s half-year financial statements for 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaron Sets 20 August 2026 Board Meeting to Approve 1H 2026 Interim Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaron Sets 20 August 2026 Board Meeting to Approve 1H 2026 Interim Results\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-08-06 16:45</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Pharmaron Beijing Co., Ltd. (Pharmaron) has issued a notice confirming that its board of directors will convene on 20 August 2026 to consider and approve the consolidated interim results for the six months ended 30 June 2026 and to authorize their publication.</p>\n<p>The announcement, dated 6 August 2026 and signed by Chairman Dr. Lou Boliang, specifies that the session will take place in Beijing, the People’s Republic of China.</p>\n<p>Pharmaron’s current board composition comprises:\n• Executive Directors: Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei  \n• Employee Representative Director: Mr. Li Shing Chung Gilbert  \n• Non-executive Director: Ms. Wan Xuan  \n• Independent Non-executive Directors: Ms. Li Lihua, Prof. Tsang King Fung, Ms. Shen Rong</p>\n<p>No additional financial details were disclosed in the notice. The forthcoming meeting will determine the release timetable and content of Pharmaron’s half-year financial statements for 2026.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龍化成","start_time":0,"source_url":"","article_id":"1182061725","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182061725","pubTimestamp":1786005958,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Pharmaron Beijing Co., Ltd. (Pharmaron) has issued a notice confirming that its board of directors will convene on 20 August 2026 to consider and approve the consolidated interim results for the six...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"康龙化成将于 2026 年 8 月 20 日召开董事会会议，批准 2026 年上半年中期业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"Pharmaron Beijing Co., Ltd. (Pharmaron) has issued a notice confirming that its board of directors will convene on 20 August 2026 to consider and approve the consolidated interim results for the six months ended 30 June 2026 and to authorize their publication.\nThe announcement, dated 6 August 2026 and signed by Chairman Dr. Lou Boliang, specifies that the session will take place in Beijing, the People’s Republic of China.\nPharmaron’s current board composition comprises:\n• Executive Directors: Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei  \n• Employee Representative Director: Mr. Li Shing Chung Gilbert  \n• Non-executive Director: Ms. Wan Xuan  \n• Independent Non-executive Directors: Ms. Li Lihua, Prof. Tsang King Fung, Ms. Shen Rong\nNo additional financial details were disclosed in the notice. The forthcoming meeting will determine the release timetable and content of Pharmaron’s half-year financial statements for 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}